EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Fibroblast Activation Protein Inhibitor Theranostics

Rainer Hamacher, Helena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, Lukas Kessler, Phyllis F Cheung, Sebastian Bauer, Ken Herrmann, Hans-Ulrich Schildhaus, Jens T Siveke, Wolfgang P Fendler

PET Clinics · 2023-07 · 18 (3) · 361-367

DOI: 10.1016/j.cpet.2023.02.008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PET Clinics, 2023-07. Verfasst von Rainer Hamacher und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, Essen, 45122 Germany; German Cancer Consortium…. Hauptthemen laut MEDLINE: Precision Medicine, Sarcoma. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The theranostic use of fibroblast activation protein inhibitors (FAPIs) is a novel approach in oncology. Sarcomas are a heterogenous group of rare malignant tumors. Prognosis remains poor in advanced/metastatic disease due to limited therapeutic options. Sarcoma frequently demonstrate high expression of fibroblast activation protein alpha on the tumor cells themselves, in contrast to other solid tumors, where it is mainly expressed on cancer-associated fibroblasts. Consequently, high in vivo uptake of FAPI in PET is observed in sarcoma. Moreover, retrospective case reports and series demonstrated feasibility of FAPI radioligand therapy with signs of tumor response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineSarcomaHumansRetrospective StudiesMedical OncologyFibroblastsPositron Emission Tomography Computed TomographyGallium Radioisotopes

Stichwörter der Autor:innen

FAP-AlphaFAPIOncologyPETRadioligandSarcomaTherapy

Substanzen

Gallium Radioisotopes

Autor:innen und Institutionen

  • Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, Essen, 45122 Germany; German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Hufelandstr. 55, Esse…
  • German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Hufelandstr. 55, Essen, 45122 Germany; Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, Esse…
  • Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, Essen, 45122 Germany; Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK…
  • German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Hufelandstr. 55, Essen, 45122 Germany; Institute of Pathology, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, Essen, 45122…

Zitieren

APA

Hamacher, R., Lanzafame, H., Mavroeidi, I. A., Pabst, K. M., Kessler, L., Cheung, P. F., Bauer, S., Herrmann, K., Schildhaus, H. U., Siveke, J. T., & Fendler, W. P. (2023). Fibroblast Activation Protein Inhibitor Theranostics. PET Clinics, 18(3), 361-367. https://doi.org/10.1016/j.cpet.2023.02.008

Vancouver

Hamacher R, Lanzafame H, Mavroeidi IA, Pabst KM, Kessler L, Cheung PF, et al. Fibroblast Activation Protein Inhibitor Theranostics. PET Clinics. 2023;18(3):361-367. doi:10.1016/j.cpet.2023.02.008

BibTeX
@article{Hamacher2023,
  author = {Hamacher, Rainer and Lanzafame, Helena and Mavroeidi, Ilektra A and Pabst, Kim M and Kessler, Lukas and Cheung, Phyllis F and Bauer, Sebastian and Herrmann, Ken and Schildhaus, Hans-Ulrich and Siveke, Jens T and Fendler, Wolfgang P},
  title = {Fibroblast Activation Protein Inhibitor Theranostics},
  journal = {PET Clinics},
  year = {2023},
  volume = {18},
  number = {3},
  pages = {361--367},
  doi = {10.1016/j.cpet.2023.02.008}
}
Kostenlos starten →